Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer is almost invariably associated with mutations in the KRAS gene, most commonly KRASG12D, that result in a dominant-active form of the KRAS GTPase. However, how KRAS mutations promote pancreatic carcinogenesis is not fully understood, and whether oncogenic KRAS is required for the maintenance of pancreatic cancer has not been established. To address these questions, we generated two mouse models of pancreatic tumorigenesis: mice transgenic for inducible KrasG12D, which allows for inducible, pancreas-specific, and reversible expression of the oncogenic KrasG12D, with or without inactivation of one allele of the tumor suppressor gene p53. Here, we report that, early in tumorigenesis, induction of oncogenic KrasG12D reversibly altered normal epithelial differentiation following tissue damage, leading to precancerous lesions. Inactivation of KrasG12D in established precursor lesions and during progression to cancer led to regression of the lesions, indicating that KrasG12D was required for tumor cell survival. Strikingly, during all stages of carcinogenesis, KrasG12D upregulated Hedgehog signaling, inflammatory pathways, and several pathways known to mediate paracrine interactions between epithelial cells and their surrounding microenvironment, thus promoting formation and maintenance of the fibroinflammatory stroma that plays a pivotal role in pancreatic cancer. Our data establish that epithelial KrasG12D influences multiple cell types to drive pancreatic tumorigenesis and is essential for tumor maintenance. They also strongly support the notion that inhibiting KrasG12D, or its downstream effectors, could provide a new approach for the treatment of pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies have demonstrated that genetic ablation of KRAS expression leads to cell cycle arrest and death in cell lines and potent tumor regressions in animal models of PDAC (5–7).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [7]
In the citing paper
“Extinguishing the expression of mutant Kras in the pancreas led to rapid tumor regression, thus demonstrating a critical role of Kras in tumor maintenance (73, 78).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [78]
In the citing paper
“Withdrawal of oncogenic Kras resulted in regression of invasive neoplasia, including regression of metastatic disease63–65.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [63]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Research works printed but not linked: 2
- Klimstra, 1994, Am J Pathol., 145, 1547
- Caldwell, Oncogene.
Cited by
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716
“To model anti-Ras therapy, we and others have generated an inducible Kras GEM PDAC model and established that extinction of Kras induced rapid tumor regression, highlighting the potential clinical utility of targeting oncogenic KRAS in pancreatic cancer (Collins et al., 2012; Ying et al., 2012).”
InfluentialRole of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Bryant, K. L., Stalnecker, C. A., Zeitouni, D., Klomp, J. E., Peng, S., Tikunov, A. P., Gunda, V., Pierobon, M., Waters, A. M., George, S. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0368-8 · Cited by 692
KRAS: feeding pancreatic cancer proliferation
Bryant, K. L., Mancias, J. D., Kimmelman, A. C., & Der, C. J. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.004 · Cited by 675
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
“In a Kras-driven mouse model, Kras upregulated Hedgehog signaling and activated the inflammatory pathway in autochthonous pancreatic tumors, which promoted the development and maintenance of a fibroinflammatory stroma resulting in T-cell exhaustion.(77) In addition, FAK was also identified as a critical regulator of t…”
BackgroundStromal biology and therapy in pancreatic cancer: a changing paradigm
Neesse, A., Algül, H., Tuveson, D. A., & Gress, T. M. (2015) · Gut · doi:10.1136/gutjnl-2015-309304 · Cited by 559
“Besides the Cre-loxP , Flp-FRT DRS, tetracycline-inducible expression systems, 43 44 novel embryonic stem cell-based PDA models 45 and recombination systems such as Dre-Rox system are valuable additions to the genomic toolbox that will spur the fi eld.”
MethodGenetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
“Interestingly, in contrast to the rapid tumor regression observed upon Kras extinction in advanced tumors (Collins et al. 2012; Ying et al. 2012), Pi3k deficiency leads to sustained tumor stasis, and gross tumor regression is only achieved upon cotreatment with a MEK inhibitor, suggesting that both…”
InfluentialOncogenic KRAS signalling in pancreatic cancer
Eser, S., Schnieke, A., Schneider, G., & Saur, D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.215 · Cited by 504
“22, 81675 München, Germany; 2German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany and 3Livestock Biotechnology, Technische Universität München, Liesel-Beckmann Str. 1., 85354 Freising,”
BackgroundInfluentialTumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance
Sherman, M. H., & Beatty, G. L. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031621-024600 · Cited by 467
Incio, J., Liu, H., Suboj, P., Chin, S. M., Chen, I. X., Pinter, M., Ng, M. R., Nia, H. T., Grahovac, J., Kao, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1177 · Cited by 456
Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0142 · Cited by 444
“In 84 preclinical models, activated KRAS has been shown to drive both the initiation and 85 maintenance of a range of cancer types (8-11).”
BackgroundBroadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
Ruscetti, M., Morris, J. P., Mezzadra, R., Russell, J., Leibold, J., Romesser, P. B., Simon, J., Kulick, A., Ho, Y.-J., Fennell, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.008 · Cited by 424
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
Roles for KRAS in Pancreatic Tumor Development and Progression
di Magliano, M. P., & Logsdon, C. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.071 · Cited by 400
Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis
Thomas, D., & Radhakrishnan, P. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0927-5 · Cited by 396
Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review
KONTOMANOLIS, E. N., KOUTRAS, A., SYLLAIOS, A., SCHIZAS, D., MASTORAKI, A., GARMPIS, N., DIAKOSAVVAS, M., ANGELOU, K., TSATSARIS, G., PAGKALOS, A., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14622 · Cited by 389
Zhang, Y., Lazarus, J., Steele, N. G., Yan, W., Lee, H.-J., Nwosu, Z. C., Halbrook, C. J., Menjivar, R. E., Kemp, S. B., Sirihorachai, V. R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0958 · Cited by 385
“PanIN lesions were induced in iKras* (Ptf1aCre;TetO-KrasG12D;R26rtTa-IRES-EGFP) mice by caerulein and doxycycline as previously described (31).”
MethodSelf-citationEfficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer
Kemp, S. B., Cheng, N., Markosyan, N., Sor, R., Kim, I.-K., Hallin, J., Shoush, J., Quinones, L., Brown, N. V., Bassett, J. B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1066 · Cited by 370
“9–13 ).”
Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
Tape, C. J., Ling, S., Dimitriadi, M., McMahon, K. M., Worboys, J. D., Leong, H. S., Norrie, I. C., Miller, C. J., Poulogiannis, G., Lauffenburger, D. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.029 · Cited by 369
“As previously established, KRAS simultaneously induces SHH secretion (Collins et al., 2012; Lauth et al., 2010) (Figure 1B) and disrupts primary cilium in PDA cells (Figure 1C).”
BackgroundResultInfluentialKRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
“Extinguishing the expression of mutant Kras in the pancreas led to rapid tumor regression, thus demonstrating a critical role of Kras in tumor maintenance (73, 78).”
BackgroundTranslational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0027 · Cited by 343
“…to be particularly addicted to oncogenic RAS signaling, exemplified by Kras G12D inactivation studies in genetically engineered mouse models (6), pharmacologic inhibition of KRAS G12D in preclinical models (7, 8), and most recently illustrated by the clinical activity of KRAS G12C…”
Pancreatic cancer: why is it so hard to treat?
Oberstein, P. E., & Olive, K. P. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13478680 · Cited by 340
“A pair of studies in genetically engineered mouse models that utilized ‘switchable’ alleles of mutant K-ras found that the loss of mutant K-ras expression led to rapid quiescence and involution of the stroma over the course of just a few days [Collins et al. 2012; Ying et al. 2012].”
BackgroundZhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F. M., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & Pasca di Magliano, M. (2017) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 337
“9 Here, by crossing CD11b-DTR mice with a mouse model of pancreatic cancer, the iKras* mouse, 10 we set out to determine the contribution of myeloid cells to the initiation, progression and maintenance of pancreatic cancer.”
MethodSelf-citationSingle-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity
Hutton, C., Heider, F., Blanco-Gomez, A., Banyard, A., Kononov, A., Zhang, X., Karim, S., Paulus-Hock, V., Watt, D., Steele, N., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.017 · Cited by 337
“Co-regulated CAF and immune subsets within the PDA tumor microenvironment In addition to fibrotic expansion, developing PDA is characterized by a co-evolving tumor-permissive inflammation (Clark et al., 2007; Collins et al., 2012).”
BackgroundMacrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Kaneda, M. M., Cappello, P., Nguyen, A. V., Ralainirina, N., Hardamon, C. R., Foubert, P., Schmid, M. C., Sun, P., Mose, E., Bouvet, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1346 · Cited by 326
A gene–environment-induced epigenetic program initiates tumorigenesis
Alonso-Curbelo, D., Ho, Y.-J., Burdziak, C., Maag, J. L. V., Morris, J. P., Chandwani, R., Chen, H.-A., Tsanov, K. M., Barriga, F. M., Luan, W., et al. (2021) · Nature · doi:10.1038/s41586-020-03147-x · Cited by 316
Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
Ullman, N. A., Burchard, P. R., Dunne, R. F., & Linehan, D. C. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02616 · Cited by 302
“The PDAC TME is characterized by a robust immune infiltrate, which comprises nearly 50% of its cellular component and is largely composed of CD451 bone marrow–derived immune cells.(16,22,45) PDAC induces an altered state of myelopoiesis, recruitment, and repolarization of these cells to promote their accumulation and…”
BackgroundMacrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs
Liou, G.-Y., Döppler, H., Necela, B., Krishna, M., Crawford, H. C., Raimondo, M., & Storz, P. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201301001 · Cited by 294
“Many cancers can arise from sites of chronic irritation, infection, or inflammation (Coussens and Werb, 2002).”
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Xiang, Y., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 287
The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer
Najumudeen, A. K., Ceteci, F., Fey, S. K., Hamm, G., Steven, R. T., Hall, H., Nikula, C. J., Dexter, A., Murta, T., Race, A. M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00753-3 · Cited by 289
Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment
Helms, E., Onate, M. K., & Sherman, M. H. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1353 · Cited by 283
“In the pancreas, early responses to oncogenic signaling in the pancreatic epithelium include the activation and expansion of fibroblasts, such that low-grade premalignant pancreatic intraepithelial neoplasia (PanIN) lesions are already surrounded by areas of fibrosis (5).”
BackgroundMechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“Prior studies have demonstrated that genetic ablation of KRAS expression leads to cell cycle arrest and death in cell lines and potent tumor regressions in animal models of PDAC (5–7).”
BackgroundTumors and Mitochondrial Respiration: A Neglected Connection
Viale, A., Corti, D., & Draetta, G. F. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0491 · Cited by 266
“Cancer Res; 75(18) September 15, 2015 Cancer Research 3688”
Zhang, Y., Yan, W., Collins, M. A., Bednar, F., Rakshit, S., Zetter, B. R., Stanger, B. Z., Chung, I., Rhim, A. D., & di Magliano, M. P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1558-t · Cited by 261
“We used a genetically engineered mouse model of pancreatic cancer, the iKras mouse, based on pancreas-specific, inducible, and reversible expression of oncogenic Kras (Kras ) recently described by our group (21).”
InfluentialSelf-citationMahadevan, K. K., McAndrews, K. M., LeBleu, V. S., Yang, S., Lyu, H., Li, B., Sockwell, A. M., Kirtley, M. L., Morse, S. J., Moreno Diaz, B. A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.002 · Cited by 258
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Grasso, C., Jansen, G., & Giovannetti, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.026 · Cited by 253
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 250
A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer
Schönhuber, N., Seidler, B., Schuck, K., Veltkamp, C., Schachtler, C., Zukowska, M., Eser, S., Feyerabend, T. B., Paul, M. C., Eser, P., et al. (2014) · Nature Medicine · doi:10.1038/nm.3646 · Cited by 237
Molecular Pathogenesis of Pancreatic Cancer
Grant, T. J., Hua, K., & Singh, A. (2016) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.09.008 · Cited by 237
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 237
Metabolic Dependencies in RAS-Driven Cancers
Kimmelman, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2425 · Cited by 224
“Indeed, inducible oncogenic Kras alleles have been used to explore these issues in pancreatic cancer (55, 56).”
BackgroundPI3K/Akt-mediated regulation of p53 in cancer
Abraham, A. G., & O’Neill, E. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140070 · Cited by 221
Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up
Perera, R. M., & Bardeesy, N. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0671 · Cited by 217
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 216
“Pancreatic cancer is characterized by an extremely high frequency of KRAS mutation (50–80 % of cases) [89, 90], and preclinical experiments have confirmed that KRAS expression is required for oncogenesis and tumor maintenance [37, 91].”
BackgroundMicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators
Daoud, A. Z., Mulholland, E. J., Cole, G., & McCarthy, H. O. (2019) · BMC Cancer · doi:10.1186/s12885-019-6284-y · Cited by 215
“[19] engineered two mouse models to have reversibly inducible K-RAS mutation that is tissue-specific.”
BackgroundERKs in cancer: friends or foes?
Deschênes-Simard, X., Kottakis, F., Meloche, S., & Ferbeyre, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2381 · Cited by 186
“pancreatic premalignant lesions and in pancreatic ductal adenocarcinoma (PDAC) cells (52, 53).”
BackgroundRas and Rap1: A tale of two GTPases
Shah, S., Brock, E. J., Ji, K., & Mattingly, R. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.005 · Cited by 211
“precancerous pancreatic lesions harbor these mutations [37], and in vivo proof of concept studies have demonstrated that while induction of RAS led to the appearance of precancerous lesions, inactivation of the gene caused regression—indicating that it is required for tumor maintenance and survival [36].”
BackgroundTumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., et al. (2024) · Nature · doi:10.1038/s41586-024-07379-z · Cited by 209
“Studies of Kras G12D gene deletion in engineered mouse models have demonstrated that mutant KRAS has an essential role in the maintenance of PDAC 17–19 .”
BackgroundCanonical Wnt Signaling Is Required for Pancreatic Carcinogenesis
Zhang, Y., Morris, J. P., Yan, W., Schofield, H. K., Gurney, A., Simeone, D. M., Millar, S. E., Hoey, T., Hebrok, M., & Pasca di Magliano, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4384 · Cited by 208
“Western blotting Western blotting was conducted as previously described (21).”
InfluentialSelf-citationLiou, G.-Y., Döppler, H., Necela, B., Edenfield, B., Zhang, L., Dawson, D. W., & Storz, P. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0474 · Cited by 203
“Overall, this suggests that macrophages can contribute to the progression of ADM to PanINs.”
BackgroundInfluentialBulle, A., & Lim, K.-H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00341-1 · Cited by 201
KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment
Dias Carvalho, P., Guimarães, C. F., Cardoso, A. P., Mendonça, S., Costa, Â. M., Oliveira, M. J., & Velho, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2084 · Cited by 202
“TheHh pathway, through the Sonic Hedgehog (SHh) protein, is known to promote myofibroblast expansion (63, 64), and its depletion was shown to reduce pancreatic ductal carcinoma (PDAC) stroma (65).”
BackgroundSwierczynski, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2279 · Cited by 198
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase–driven tumors
Jameson, K. L., Mazur, P. K., Zehnder, A. M., Zhang, J., Zarnegar, B., Sage, J., & Khavari, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3165 · Cited by 197
Kemp, S. B., Carpenter, E. S., Steele, N. G., Donahue, K. L., Nwosu, Z. C., Pacheco, A., Velez-Delgado, A., Menjivar, R. E., Lima, F., The, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3929 · Cited by 197
“To determine if oncogenic Kras in the epithelium regulates ApoE expression in vivo, we utilized the iKras* mouse model of PDA (19), where oncogenic Kras (Kras*) expression is inducible and”
MethodInfluentialSelf-citationNew biomarkers and targets in pancreatic cancer and their application to treatment
Costello, E., Greenhalf, W., & Neoptolemos, J. P. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.119 · Cited by 195
KRAS drives immune evasion in a genetic model of pancreatic cancer
Ischenko, I., D’Amico, S., Rao, M., Li, J., Hayman, M. J., Powers, S., Petrenko, O., & Reich, N. C. (2021) · Nature Communications · doi:10.1038/s41467-021-21736-w · Cited by 191
Patra, K. C., Kato, Y., Mizukami, Y., Widholz, S., Boukhali, M., Revenco, I., Grossman, E. A., Ji, F., Sadreyev, R. I., Liss, A. S., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0122-3 · Cited by 192
KRAS-related proteins in pancreatic cancer
Mann, K. M., Ying, H., Juan, J., Jenkins, N. A., & Copeland, N. G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.003 · Cited by 187
Metastatic pancreatic cancer is dependent on oncogenic Kras in mice
Collins, M. A., Brisset, J.-C., Zhang, Y., Bednar, F., Pierre, J., Heist, K. A., Galbán, C. J., Galbán, S., & di Magliano, M. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049707 · Cited by 178
“KPC mice [4] and iKras*p53 mice [8] were previously described.”
BackgroundMethodResultInfluentialSelf-citationMYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype
Sodir, N. M., Kortlever, R. M., Barthet, V. J. A., Campos, T., Pellegrinet, L., Kupczak, S., Anastasiou, P., Swigart, L. B., Soucek, L., Arends, M. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0435 · Cited by 182
Genetically engineered mouse models of pancreatic adenocarcinoma
Guerra, C., & Barbacid, M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.002 · Cited by 179
“Stroma remodeling is a process that mostly depends on oncogenic KRas signaling, since acute loss of mutant KRas in established PDAC tumors results in rapid quiescence and involution of the stroma cells (Collins et al., 2012).”
BackgroundKRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
Zeitouni, D., Pylayeva-Gupta, Y., Der, C., & Bryant, K. (2016) · Cancers · doi:10.3390/cancers8040045 · Cited by 179
“With significant and compelling evidence that aberrant KRAS protein function is critical for PDAC growth and maintenance [8–10], the Pancreatic Cancer Working Group (NCI) identified targeting KRAS as one of four key priorities for pancreatic cancer research [11].”
BackgroundKaiser, C. E., Van Ert, N. A., Agrawal, P., Chawla, R., Yang, D., & Hurley, L. H. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b02046 · Cited by 179
Datta, J., Dai, X., Bianchi, A., De Castro Silva, I., Mehra, S., Garrido, V. T., Lamichhane, P., Singh, S. P., Zhou, Z., Dosch, A. R., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.07.076 · Cited by 178
Arginase 1 is a key driver of immune suppression in pancreatic cancer
Menjivar, R. E., Nwosu, Z. C., Du, W., Donahue, K. L., Hong, H. S., Espinoza, C., Brown, K., Velez-Delgado, A., Yan, W., Lima, F., et al. (2023) · eLife · doi:10.7554/elife.80721 · Cited by 177
“At current, specific inhibitors for KRASG12D are still not clinically available (Liu, Wang, & Li, 2019).”
BackgroundInfluentialSelf-citationRoss, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177
KRAS Controls Pancreatic Cancer Cell Lipid Metabolism and Invasive Potential through the Lipase HSL
Rozeveld, C. N., Johnson, K. M., Zhang, L., & Razidlo, G. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1255 · Cited by 165
“Activating mutations ofKRAS drive andmaintain greater than 90% of pancreatic cancers (18, 34, 47).”
BackgroundPlasticity and Dedifferentiation within the Pancreas: Development, Homeostasis, and Disease
Puri, S., Folias, A. E., & Hebrok, M. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2014.11.001 · Cited by 162
“In the mouse model of pancreatic cancer, removal of oncogenic Kras activity in established precursor lesions can revert the cells back to an acinar fate and reduce tumor burden (Collins et al., 2012; Ying et al., 2012), pointing to a need for the development of Kras inhibitors.”
Uridine-derived ribose fuels glucose-restricted pancreatic cancer
Nwosu, Z. C., Ward, M. H., Sajjakulnukit, P., Poudel, P., Ragulan, C., Kasperek, S., Radyk, M., Sutton, D., Menjivar, R. E., Andren, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06073-w · Cited by 159
Barriers and opportunities in pancreatic cancer immunotherapy
Ju, Y., Xu, D., Liao, M.-M., Sun, Y., Bao, W.-D., Yao, F., & Ma, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00681-z · Cited by 159
“It has also been shown that mKRAS recruits immunosuppressive IL-17-producing T cells 35 and promotes the formation and maintenance of fi bro-in fl ammatory stroma 123 .”
BackgroundKnockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells
Lu, Y., Zhu, H., Shan, H., Lu, J., Chang, X., Li, X., Lu, J., Fan, X., Zhu, S., Wang, Y., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.009 · Cited by 160
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Hou, P., Kapoor, A., Zhang, Q., Li, J., Wu, C.-J., Li, J., Lan, Z., Tang, M., Ma, X., Ackroyd, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0597 · Cited by 154
“61 KRAS* also supports PDAC tumor maintenance by regulating several intrinsic and extrinsic 62 cancer hallmarks (5, 6).”
BackgroundTargeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk
Orozco, C. A., Martinez-Bosch, N., Guerrero, P. E., Vinaixa, J., Dalotto-Moreno, T., Iglesias, M., Moreno, M., Djurec, M., Poirier, F., Gabius, H.-J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1722434115 · Cited by 158
“Another key hallmark of PDA is KRAS mutations, which are present in >90% of PDA patients (24) and are essential for tumor initiation and progression (53, 54).”
BackgroundXie, Y., Hang, Y., Wang, Y., Sleightholm, R., Prajapati, D. R., Bader, J., Yu, A., Tang, W., Jaramillo, L., Li, J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b03978 · Cited by 158
The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance
Biancur, D. E., & Kimmelman, A. C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.011 · Cited by 152
“Despite the complexity of PDA initiation, it has been established that the KRAS mutation is a key driver of tumor progression and multiple studies report that tumors are highly dependent on this oncogene for tumor maintenance [7, 8].”
BackgroundA Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Wei, D., Wang, L., Zuo, X., Maitra, A., & Bresalier, R. S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2098 · Cited by 192
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
Carpenter, E. S., Elhossiny, A. M., Kadiyala, P., Li, J., McGue, J. J., Griffith, B. D., Zhang, Y., Edwards, J., Nelson, S., Lima, F., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0013 · Cited by 171
“Although mouse models have been instrumental to understanding the early stages of pancreas carcinogenesis and to studying the healthy organ (36–39), they are a poor substitute for human samples.”
Self-citationKeenan, B. P., Saenger, Y., Kafrouni, M. I., Leubner, A., Lauer, P., Maitra, A., Rucki, A. A., Gunderson, A. J., Coussens, L. M., Brockstedt, D. G., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.055 · Cited by 148
Nagarajan, A., Dogra, S. K., Sun, L., Gandotra, N., Ho, T., Cai, G., Cline, G., Kumar, P., Cowles, R. A., & Wajapeyee, N. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.07.014 · Cited by 144
“PON2 Cooperates with KRAS to Promote PDAC Tumor Growth Mutations of the KRAS gene (typically for KRAS) are present in over 90% of PDAC tumors and are necessary for PDAC initiation and tumor maintenance (Collins et al., 2012).”
BackgroundAcid and the basis for cellular plasticity and reprogramming in gastric repair and cancer
Sáenz, J. B., & Mills, J. C. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.5 · Cited by 153
von Figura, G., Morris, J. P., Wright, C. V. E., & Hebrok, M. (2014) · Gut · doi:10.1136/gutjnl-2012-304287 · Cited by 143
Mills, J. C., & Sansom, O. J. (2015) · Science Signaling · doi:10.1126/scisignal.aaa7540 · Cited by 152
Genetically Engineered Mouse Models of Pancreatic Cancer
Westphalen, C. B., & Olive, K. P. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31827ab4c4 · Cited by 139
“The acute loss of mutant K-ras quickly resulted in profound alterations in tumor cell metabolism and dramatic reorganization and involution of the desmoplastic stroma.(47,48) The Cancer Journal & Volume 18, Number 6, November/December 2012 Genetically Engineered Models of Pancreatic Cancer”
BackgroundCell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma
Lee, A. Y. L., Dubois, C. L., Sarai, K., Zarei, S., Schaeffer, D. F., Sander, M., & Kopp, J. L. (2019) · Gut · doi:10.1136/gutjnl-2017-314426 · Cited by 139
Zhao, X., Liu, L., Lang, J., Cheng, K., Wang, Y., Li, X., Shi, J., Wang, Y., & Nie, G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.042 · Cited by 136
Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer
Kang, R., Xie, Y., Zhang, Q., Hou, W., Jiang, Q., Zhu, S., Liu, J., Zeng, D., Wang, H., Bartlett, D. L., et al. (2017) · Cell Research · doi:10.1038/cr.2017.51 · Cited by 140
Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets
Whittle, M. C., & Hingorani, S. R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.044 · Cited by 137
PI3K Regulation of RAC1 Is Required for KRAS-Induced Pancreatic Tumorigenesis in Mice
Wu, C.-Y. C., Carpenter, E. S., Takeuchi, K. K., Halbrook, C. J., Peverley, L. V., Bien, H., Hall, J. C., DelGiorno, K. E., Pal, D., Song, Y., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.032 · Cited by 135
“Nearly all PDAs harbor oncogenic mutations in the KRAS gene,(5) and pancreatic tumor maintenance is compromised when KRAS signaling is extinguished.(6,7) Although pharmacological inhibition of KRAS has thus far been unsuccessful,(8) oncogenic KRAS activates downstream kinase effectors such as RAF-MEK and PI3K-AKT that…”
Cogoi, S., Ferino, A., Miglietta, G., Pedersen, E. B., & Xodo, L. E. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1142 · Cited by 135
The biological underpinnings of therapeutic resistance in pancreatic cancer
Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 159
“Interestingly, inactivation of KRAS at an early stage of cancer conception causes not only lesion regression but also resolution of the desmoplastic stroma (Collins et al. 2012; Ying et al. 2012).”
Background
Metadata
- Authors
- Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M.
- Affiliations
- University of Michigan (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2012-02-01
- Volume
- 122
- Issue
- 2
- Pages
- 639-653
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3266788
- OpenAlex
- W2018159884
- Cited by
- 770
- References
- 66
- Citations by year
- 2026: 40 · 2025: 41 · 2024: 53 · 2023: 63 · 2022: 71 · 2021: 80 · 2020: 51 · 2019: 43 · 2018: 54 · 2017: 69 · 2016: 56 · 2015: 45 · 2014: 52 · 2013: 41 · 2012: 11
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Pancreatic Cancer Action Network
- American College of Surgeons
- Vanderbilt University
- University of Pennsylvania
- University of Michigan
- National Institutes of Health (NIH T32, P30 DK, 5-T32-HD007515)
- National Cancer Institute (R01CA151588, P50CA130810, P50CA13810)
- National Institute of General Medical Sciences (T32GM07315, T32GM007315)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (5-T32-HD007515, T32HD007505)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, KRAS G12D, oncogenic KRAS, pancreatic carcinogenesis, tumor maintenance, p53, precancerous lesions, epithelial differentiation, Hedgehog signaling, inflammation, tumor microenvironment, tumor regression, KRAS inhibition
- MeSH terms
- Animals, Cell Differentiation, Cell Transformation, Neoplastic, Disease Models, Animal, Epithelial Cells, Humans, Mice, Transgenic, Pancreatic Neoplasms, Pancreatitis, Signal Transduction, Survival Rate, Proto-Oncogene Proteins p21(ras), Mice, Hedgehog Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.